Hemophagocytic lymphohistiocytosis (HLH) is a severe and potentially deadly condition associated with extensive inflammation and immune activation. Cytokine adsorption may serve as a supportive treatment that can stabilize organ function in affected patients by reducing their circulating cytokines levels. To date, no descriptions of clinical experiences associated with the use of HA330-II column hemoadsorption for the treatment of HLH children have been published. Herein, we describe one case of a children with Epstein-Barr virus (EBV)-associated HLH that underwent hemoadsorption therapy with HA330-II perfusion cartridge. Following treatment, the patient exhibited substantial reductions in plasma interleukin (IL)-6, IL-8, IL-10, and interferon (IFN)-γ levels with concomitant stabilization of organ functionality, underscoring the efficacy of the HA330-II perfusion column. Owing to a lack of improved liver function, sequential chemotherapy combined with hemoadsorption therapy were performed and ultimately achieved satisfactory survival outcomes for this patient.